Why Recursion Pharmaceuticals Stock Caught a Cold This Week
Recursion Pharmaceuticals (NASDAQ: RXRX) saw its stock drop over 17% week-to-date following a price target cut by Morgan Stanley analyst ...
Recursion Pharmaceuticals (NASDAQ: RXRX) saw its stock drop over 17% week-to-date following a price target cut by Morgan Stanley analyst ...
Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results, leading to a more than 17% drop in shares during early trading ...
In a recent episode of the Motley Fool Scoreboard, expert analysts delve into Kiniksa Pharmaceuticals (NASDAQ: KNSA), offering insights on ...
Read a summary of this article on FAST.SINGAPORE: Deputy Prime Minister Gan Kim Yong announced that the US is open ...
Danish drugmaker Novo Nordisk presented its annual report in Bagsvaerd, Denmark, showcasing flags with the company's logos, including those of ...
Novo Nordisk defended disappointing trial results for its obesity drug candidate CagriSema, emphasizing its importance as a weight loss treatment ...
Danish drugmaker Novo Nordisk showcased flags featuring the logos of their popular diabetes and weight-loss treatments Ozempic and Wegovy during ...
Novo Nordisk's hopes of revolutionizing obesity treatment with its CagriSema drug have been cast into doubt following disappointing trial results, ...
Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a ...
The U.S. health regulator has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active ...
Copyright © 2025 News Wave
News Wave is not responsible for the content of external sites.
Copyright © 2025 News Wave
News Wave is not responsible for the content of external sites.